PARIS, September 02, 2025--(BUSINESS WIRE)--BrightHeart, a pioneer in AI-driven prenatal ultrasound evaluation, today announced the publication of its landmark study in Obstetrics & Gynecology, ...

PARIS--(BUSINESS WIRE)--BrightHeart, a Paris-based company developing an AI solution for the prenatal detection of congenital heart defects, announced today the appointment of Michael Butchko as an ...

BrightHeart has received the US Food and Drug Administration (FDA) 510(k) clearance for its AI software to transform the foetal heart’s prenatal ultrasound evaluations. This development represents an ...

PARIS--(BUSINESS WIRE)--BrightHeart, a leading AI innovator in obstetric and pediatric cardiology technology, is delighted to announce the appointment of Michael Butchko as the new Chairman of the ...

BrightHeart has gained a further 510(k) clearance from the US Food and Drug Administration (FDA) for its AI-based prenatal congenital heart defect (CHD) screening platform. Building on the initial FDA ...

BrightHeart has raised €11m ($12.8m) in funding to advance commercialisation efforts for its artificial intelligence (AI)-based prenatal congenital heart defect (CHD) screening platform. The French ...

BrightHeart, a global leader in artificial intelligence (AI) solutions for prenatal ultrasound, today announced the closing of an €11 million Series A financing round. The round was co-led by Odyssée ...

BrightHeart, a global leader in AI-driven prenatal ultrasound, today announced the availability of its B-Right AI Platform through GE HealthCare’s Voluson™ Solution Store, bringing advanced AI support ...

BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, announced today the 510(k) clearance for updates to the BrightHeart platform, adds the ...

BrightHeart's technology is claimed to be alleviating the strain on overburdened sonographers and OB/GYNs. Credit: Andrey_Popov / Shutterstock. BrightHeart has received the US Food and Drug ...